Theravance Biopharma is advancing TD-0903, a lung-selective nebulized Janus kinase inhibitor (JAKi) into clinical development to assess its utility in preventing the cytokine storm associated with Acute Lung Injury (ALI) in patients hospitalized due to COVID-19, with the ultimate goal of preventing progression to Acute Respiratory Distress Syndrome (ARDS). Read more...
Biohaven Pharmaceutical announced it submitted Pre-IND/IND material to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 study of vazegepant, an intranasal, high-affinity calcitonin gene-related peptide (CGRP) receptor antagonist, for the treatment of COVID-19 infection associated pulmonary complications. Read more...
Mylan Chairman Robert J. Coury and Chief Executive Officer Heather Bresch provided additional detail regarding the company's efforts to meet public health needs amid the evolving COVID-19 pandemic. Read more...